for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up
Company News

Samsung BioLogics says mass producing Eli Lilly's COVID-19 treatments

SEOUL, Nov 17 (Reuters) - Samsung BioLogics said on Tuesday that it is mass producing COVID-19 antibody treatments developed by Eli Lilly and Co.

The South Korean pharmaceutical contract manufacturer said in a statement that it had signed a manufacturing contract with Eli Lilly in May to address the global demand for COVID-19 treatments. (Reporting by Joyce Lee; Editing by Jacqueline Wong)

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up